Pluristyx, Inc

Pluristyx was established in 2018 as an advanced therapy tools company to help companies and researchers solve manufacturing challenges in the field of drug development, regenerative medicine, and cell and gene therapy. Pluristyx has provided seamless client support by offering CMC consulting, contract development services, and research- and clinical-grade Ready-To-Differentiate (RTD®) Pluripotent Stem Cells at a commercial scale. In doing so, Pluristyx effectively decouples the hassles of expansion and banking from differentiation and product development, allowing early-stage companies to focus precious resources on therapeutic application rather than manufacturing hurdles, with the goal of advancing promising laboratory discoveries into patients. Pluristyx has a developed a proprietary footprint-free method to generate induced Pluripotent Stem Cells (iPSCs) from clinically-relevant starting material. Pluristyx iPSCs are manufactured at scale and cryopreserved at high-density in a Ready-to-Differentiate® (RTD®) format that can be immediately thawed for downstream differentiation without the need for additional expansion. Pluristyx also provides the consulting and process development support required to incorporate these RTD®-iPSCs into existing workflows to accelerate product development and clinical translation. In October, 2022 Pluristyx announced a merger with panCELLa. Pluristyx today offers a portfolio of iPSC-based products and services to provide end-to-end client support in early product development, while panCELLa offers an array of unique and effective technologies with particular strength in gene editing. As one company, Pluristyx and panCELLa offer an enlarged portfolio whose long-term focus is to become the global leader in clinical-grade, genetically modified, “off-the-shelf” iPSCs with the lowest barrier to entry for cell therapy development, providing clients with the fastest speed to clinic and the best route to commercialization.